COVID-19 and Cancer: Discovery of Difference in Clinical Immune Indexes

Objective. This study explored the consistency and differences in the immune cells and cytokines between patients with COVID-19 or cancer. We further analyzed the correlations between the acute inflammation and cancer-related immune disorder. Methods. This retrospective study involved 167 COVID-19 patients and 218 cancer patients. COVID-19 and cancer were each further divided into two subgroups. Quantitative and qualitative variables were measured by one-way ANOVA and chi-square test, respectively. Herein, we carried out a correlation analysis between immune cells and cytokines and used receiver operating characteristic (ROC) curves to discover the optimal diagnostic index. Results. COVID-19 and cancers were associated with lymphopenia and high levels of monocytes, neutrophils, IL-6, and IL-10. IL-2 was the optimal indicator to differentiate the two diseases. Compared with respiratory cancer patients, COVID-19 patients had lower levels of IL-2 and higher levels of CD3(+)CD4(+) T cells and CD19(+) B cells. In the subgroup analysis, IL-6 was the optimal differential diagnostic parameter that had the ability to identify if COVID-19 patients would be severely affected, and severe COVID-19 patients had lower levels of lymphocyte subsets (CD3(+) T cells, CD3(+)CD4(+) T cells, CD3(+)CD8(+)T cells, and CD19(+) B cells) and CD16(+)CD56(+) NK cells and higher level of neutrophils. There were significant differences in the levels of CD3(+)CD4(+) T cells and CD19(+) B cells between T1-2 and T3-4 stages as well as IL-2 and CD19(+) B cells between N0-1 and N2-3 stages while no significant differences between the metastatic and nonmetastatic cancer patients. Additionally, there were higher correlations between IL-2 and IL-4, TNF-alpha and IL-2, TNF-alpha and IL-4, TNF-alpha and IFN-gamma, and CD16(+)CD56(+)NK cells and various subsets of T cells in COVID-19 patients. There was a higher correlation between CD3(+)CD4(+) T cells and CD19(+) B cells in cancer patients. Conclusion. Inflammation associated with COVID-19 or cancer had effects on patients' outcomes. Accompanied by changes in immune cells and cytokines, there were consistencies, differences, and satisfactory correlations between patients with COVID-19 and those with cancers.